Alumis Inc. (NASDAQ:ALMS – Get Free Report)’s share price reached a new 52-week low during trading on Monday after Oppenheimer lowered their price target on the stock to $28.00. Oppenheimer currently has an outperform rating on the stock. Alumis traded as low as $5.22 and last traded at $5.1960, with a volume of 319,044 shares traded. The stock had previously closed at $5.60.
A number of other brokerages have also recently weighed in on ALMS. Morgan Stanley dropped their target price on shares of Alumis from $39.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, September 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a report on Wednesday, September 16th. Weiss Ratings raised shares of Alumis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. HC Wainwright lowered their price objective on shares of Alumis from $15.00 to $9.00 and set a “buy” rating for the company in a research report on Friday. Finally, Benchmark reiterated a “buy” rating on shares of Alumis in a research note on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Alumis presently has an average rating of “Moderate Buy” and a consensus target price of $31.27.
Get Our Latest Research Report on Alumis
Insider Buying and Selling
In related news, Director Srinivas Akkaraju acquired 546,581 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was purchased at an average cost of $10.63 per share, for a total transaction of $5,810,156.03. Following the purchase, the director directly owned 4,937,026 shares in the company, valued at $52,480,586.38. This represents a 12.45% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 99,754 shares of company stock worth $1,037,804. 33.70% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Alumis
Hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP increased its holdings in shares of Alumis by 188.7% in the 3rd quarter. Marshall Wace LLP now owns 1,062,571 shares of the company’s stock worth $7,852,000 after acquiring an additional 694,557 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Alumis during the 3rd quarter valued at about $706,000. Polymer Capital Management US LLC acquired a new position in Alumis during the 3rd quarter valued at about $152,000. First Trust Advisors LP grew its position in Alumis by 244.8% in the 3rd quarter. First Trust Advisors LP now owns 324,311 shares of the company’s stock worth $2,397,000 after purchasing an additional 230,265 shares during the last quarter. Finally, Ieq Capital LLC bought a new position in Alumis in the 3rd quarter worth about $306,000.
Alumis Trading Down 8.7%
The firm’s 50-day simple moving average is $7.24 and its 200 day simple moving average is $20.46. The stock has a market cap of $662.06 million, a P/E ratio of -1.47 and a beta of -0.28.
Alumis (NASDAQ:ALMS – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.03. The company had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $1.90 million. Alumis had a negative return on equity of 89.77% and a negative net margin of 5,844.54%. On average, analysts anticipate that Alumis Inc. will post -2.95 EPS for the current year.
Alumis Company Profile
Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.
See Also
- Five stocks we like better than Alumis
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
